Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Zealand Pharma A/S
  6. Summary
    ZEAL   DK0060257814

ZEALAND PHARMA A/S

(ZEAL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
141.5(c) 140(c) 138(c) 138(c) 132.4 Last
124 517 140 156 143 090 403 110 83 237 Volume
-1.74% -1.06% -1.43% 0.00% -4.06% Change
More quotes
Estimated financial data (e)
Sales 2021 291 M 44,3 M 44,3 M
Net income 2021 -1 007 M -153 M -153 M
Net cash position 2021 767 M 117 M 117 M
P/E ratio 2021 -4,80x
Yield 2021 -
Sales 2022 437 M 66,6 M 66,6 M
Net income 2022 -1 075 M -164 M -164 M
Net cash position 2022 535 M 81,4 M 81,4 M
P/E ratio 2022 -5,02x
Yield 2022 -
Capitalization 5 965 M 909 M 908 M
EV / Sales 2021 17,9x
EV / Sales 2022 12,4x
Nbr of Employees 346
Free-Float 99,0%
More Financials
Company
Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and... 
Sector
Biotechnology & Medical Research
Calendar
03/10 | 09:00amEarnings Release
More about the company
Ratings of Zealand Pharma A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ZEALAND PHARMA A/S
01/20Zealand Pharma Completes Enrollment in Phase 3 Trial of Short Bowel Syndrome Treatment ..
MT
01/20Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide ..
AQ
01/19ZEALAND PHARMA MAJOR SHAREHOLDER ANN : The Capital Group Companies, January 2022
AQ
01/14European ADRs Move Higher in Friday Trading
MT
01/12Scandion Oncology enhances its external communication
AQ
01/03Zealand Pharma to Participate in H.C. Wainwright BIOCONNECT 2022 Conference
AQ
2021European ADRs Move Higher in Monday Trading
MT
2021ZEALAND PHARMA MAJOR SHAREHOLDER ANN : The Capital Group Companies, 2021
AQ
2021European ADRs Move Higher in Thursday Trading
MT
2021European ADRs Rising Wednesday
MT
2021European ADRs Move Higher in Thursday Trading
MT
2021Zealand Pharma Enrolls Last Patient for Interim Analysis of Phase 3 Short Bowel Syndrom..
MT
2021Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE..
GL
2021Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE..
CI
2021ZEALAND PHARMA A/S : Announces Seven-Year, $200 Million Financing Agreement with Oberland ..
PU
More news
News in other languages on ZEALAND PHARMA A/S
01/14Les ADR européens sont en hausse vendredi
01/11AVIS D'ANALYSTES DU JOUR : Capgemini, FDJ, SAP, Adidas, Shop Apotheke, Lindt, Swatch, Monc..
2021Les ADR européens en hausse lundi
2021Les ADR européens sont en hausse jeudi
2021Hausse des ADR européens mercredi
More news
Analyst Recommendations on ZEALAND PHARMA A/S
More recommendations
Chart ZEALAND PHARMA A/S
Duration : Period :
Zealand Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZEALAND PHARMA A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 138,00 DKK
Average target price 249,80 DKK
Spread / Average Target 81,0%
EPS Revisions
Managers and Directors
Emmanuel Dulac President & Chief Executive Officer
Matthew D. Dallas Chief Financial Officer & Senior Vice President
Alf Gunnar Martin Nicklasson Chairman
Adam Sinding Steensberg Chief Medical Officer, EVP-Research & Development
Danilo Verge Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
ZEALAND PHARMA A/S-4.89%909
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-6.39%51 206
BIONTECH SE-39.28%37 805